Powering microbiome discovery
Fast, reliable microbiome analysis using cutting-edge genomics and informatics.
Diversigen represents over a century of microbiome experience demonstrated by more than 300 scientific publications and over 100,000 citations in respected scientific journals.
HOW WE STUDY THE MICROBES LIVING IN YOUR GUT
Dan Knights PhD
Fast. Accurate. Predictive.
Accelerate Your Discoveries
Diversigen offers fast, reliable microbiome analysis using cutting-edge genomics and informatics. We help customers with study design and collection through to data generation and full custom analysis.
Precise. Controlled. Scaleable.
Expert Microbiome Analysis
Quality is everything.
We control every step of microbiome analysis, from the moment your samples are collected to the final data analysis.
Iterate faster. Get insight sooner.
Our platform is designed around generating fast, accurate, massive data sets to help you iterate the scientific process and get to insights faster.
Diversigen combines meticulous sample processing and DNA sequencing with machine learning to help you discover the next breakthrough.
Neutral. Stable. Reproducible.
Samples not collected yet?
Ask about OMNIgene® collection kits from our sister company, DNA Genotek. Take a ‘snapshot’ of the in vivo state right at the moment of collection. Ensure your microbiome profiles represent the phenotype of interest, not artifacts of overgrowth or degradation.
In the news
If you’ve attended recent conferences focused on life sciences, you might have heard the phrase “multiomics brings together all the puzzle pieces,” or something similar. More research has begun to adopt this new approach of bringing together multiple “omes” in a study to see a better picture than if you
“Crohn’s disease and Colitis collectively are inflammatory bowel diseases (IBD). These inflammatory diseases impact the gastrointestinal tract (although not exclusively gastrointestinal tract). Most of these diseases can have an autoimmune component, particularly Crohn’s disease. Crohn’s disease can affect any part of the gastrointestinal tract anywhere from the mouth to the
Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board Joins Diversigen’s Scientific Advisory Board Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board PAUL, MN, January 25, 2021 – Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ: OSUR), today announced that Eric Pamer, M.D., Professor
Discover where our services can take you.
Diversigen provides services and generates data for research purposes only. Not all services are available in all regions.